	US 12,145,972 B2
	Neuregulin-4 compounds and methods of use
Jonathan Wesley Day, Carmel, IN (US); Josef George Heuer, Carmel, IN (US); Avinash Muppidi, Carmel, IN (US); Wei Ni, Indianapolis, IN (US); and James David Pancook, San Diego, CA (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Dec. 22, 2021, as Appl. No. 17/559,430.
Application 17/559,430 is a continuation of application No. 16/835,787, filed on Mar. 31, 2020, granted, now 11,242,370.
Claims priority of provisional application 62/827,386, filed on Apr. 1, 2019.
Prior Publication US 2022/0112255 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 9/04 (2006.01); C07K 14/475 (2006.01); A61K 38/00 (2006.01); A61M 5/142 (2006.01)

CPC C07K 14/4756 (2013.01) [A61P 9/04 (2018.01); A61K 38/00 (2013.01); A61M 5/14248 (2013.01); C07K 2319/30 (2013.01)]

29 Claims

1. A compound comprising the formula:

GHEEPCGX₈SHKSFCLNGGLCYX₂₂IPTX₂₆PSPFCRCVX₃₅NYTGARC

EX₄₄VFL

wherein:

X₈is E or P;

X₂₂is Q or V;

X₂₆is F or I;

X₃₅is E or A; and

X₄₄is H, K or E

(SEQ ID NO:2) and wherein the compound optionally comprises an N-terminal extension selected from the group consisting of T, PT, MPT, S, GS, GGS, GGGS (SEQ ID NO:20), and (GGGGX_λ)_nwherein X_λ is Q, A, E or S and n=1-5 (SEQ ID NO:5).